At the endpoint of tumor inhibition experiment, the tumor weight of nanovaccine group and anti-CTLA-4 mAb group was significantly lower than that of PBS group, and the tumor weight of the combo group was significantly lower than that of each single treatment group. The gene discussed is CTLA4; the disease is neoplasm.